被动散射质子束治疗Ⅰ期非小细胞肺癌的疗效
该研究回顾性分析了2016年1月至2019年12月接受质子束治疗的42例Ⅰ期非小细胞肺癌患者,其中部分采用立体定向消融放疗(SABR)或大分割放疗。中位随访40个月,3年总生存率71.8%,3年局部控制率91.5%,3年无进展生存率66.9%,未观察到4级或5级毒性。
要点
- 质子束治疗Ⅰ期NSCLC的3年局部控制率达91.5%,3年总生存率71.8%。
- 未观察到4级或5级毒性,提示该方案安全性可接受。
核心结论
- 被动散射质子束治疗用于不可手术或拒绝手术的Ⅰ期NSCLC患者安全,局部控制率高。
研究设计与样本
- 回顾性分析2016年1月至2019年12月接受质子束治疗的42例Ⅰ期NSCLC患者,初始计划剂量为60 CGE分4次,剂量体积约束无法满足时序贯调整方案。
主要发现
- 中位随访40个月(四分位距32-48个月),42例中33例有病理确诊,其中腺癌21例(64%)。
- 3年总生存率71.8%,3年局部控制率91.5%,3年无进展生存率66.9%。
关键数值与推荐
- 中位总剂量50 CGE(范围50-70 CGE),对应中位BED10为112.5 CGE(范围96-150 CGE)。
- 初始计划剂量方案为60 CGE分4次。
临床怎么用
- 对不可手术或拒绝手术的Ⅰ期NSCLC患者,可考虑被动散射质子束SABR或大分割放疗,需根据剂量体积约束个体化调整剂量。
局限性
- 回顾性设计、样本量42例、单中心,随访时间及剂量方案异质性可能影响结论外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To investigate the treatment outcomes of passive scattering proton beam therapy using stereotactic ablative radiotherapy (SABR) or hypofractionated radiation therapy (RT) for inoperable patients or those who refused surgery for stage I non-small cell lung cancer (NSCLC). METHODS: From January 2016 to December 2019, we retrospectively analyzed 42 patients with stage I NSCLC treated with proton beam therapy. The initially intended dose regimen was 60 cobalt Gray equivalents (CGE) in 4 fractions; however, sequentially modified dose regimens were used when the dose-volume constraints could not be met. The median total dose was 50 CGE (range 50-70 CGE), while the corresponding median biologically effective dose using [Formula: see text]= 10 (BED10) was 112.5 CGE (range 96-150 CGE). RESULTS: The median follow-up time was 40 months (interquartile range 32-48 months). Among the 42 treated patients, 33 had pathologically proven cancers of which most were adenocarcinoma (n = 21, 64%). The 3-year overall survival rate was 71.8%. The estimated rates of local control and progression free survival at 3 years were 91.5% and 66.9%, respectively. Thirteen patients experienced disease progression consisting of three local, six regional, and nine distant failures. No grade 4 or 5 toxicities were observed. CONCLUSION: Passive scattering proton beam therapy for stage I NSCLC using SABR or hypofractionated RT was safe and showed high LC rates.
引用
- Bayasgalan U, Moon SH, Jeong JH, et al. Treatment outcomes of passive scattering proton beam therapy for stage I non-small cell lung cancer. Radiat Oncol. 2021. PMID: 34407855. doi:10.1186/s13014-021-01855-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。